Pi3k inhibitor for treatment of respiratory disease
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsAugustin AMOUR, Julie Nicole HAMBLIN, Edith HESSEL, David MICHALOVICH, Srividya SRISKANTHARAJAH
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds and pharmaceutically acceptable salts thereof which are inhibitors of the activity or function of the phosphoinositide 3′OH kinase family (hereinafter PI3K) for use in the treatment or prevention of respiratory infections, the treatment of airway damage, and/or the prevention of airway injury in patients with a PI3Kδ mutation.
Claims12
1-10. (canceled)
A method of treating or preventing a respiratory infection, treating airway damage, and/or preventing airway injury in a patient with a PI3Kδ mutation comprising administering a safe and effective amount of a compound of formula(I):
- wherein
- R1 is
- and
- R2 is
- or
- R1 is
- and
- R2 is
- or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
12-14. (canceled)
A method of evaluating therapy with a compound of formula (I):
- wherein
- R1 is
- and
- R2 is
- or
- R1 is
- and
- R2 is
- , or a pharmaceutically acceptable salt thereof, comprising:
- a) obtaining a sample from the patient,
- b) testing for a PI3Kδ mutation, and
- c) determining if the patient should undergo therapy with a compound of formula (I), or a pharmaceutically acceptable salt thereof, if a PI3Kδ mutation is present.
Dependencies are inferred from the claim text.